Isovaleric Acidemia

Definition And Etiology

Failure to convert Isovaleryl-CoA to 3-Methylcrotonyl-CoA in the leucine degradation pathway.
Leads to the accumulation of isovaleric acid and toxic metabolites including Isovalerylcarnitine (C5), Isovalerylglycine, and 3-Hydroxyisovaleric acid.
Toxic metabolites induce severe encephalopathy and bone marrow suppression.
Causes secondary carnitine deficiency via urinary loss of isovalerylcarnitine, and secondary hyperammonemia due to urea cycle inhibition.

The clinical presentation is highly variable and categorized into three main phenotypic forms.

Clinical Form	Onset	Characteristic Manifestations
Acute Neonatal	First few days of life	Sepsis-like presentation with poor feeding, vomiting, lethargy, and coma. Pathognomonic "Sweaty Feet" or "Rancid Cheese" odor. Severe hypotonia, seizures, and cerebral edema.
Chronic Intermittent	Infancy or childhood	Recurrent episodes of vomiting, lethargy, and ketoacidosis resembling diabetic ketoacidosis. Triggered by catabolic stress (infection, fasting) or high protein intake. Complications include acute pancreatitis, neutropenia, pancytopenia, and failure to thrive.
Asymptomatic	Detected via Newborn Screening (NBS)	Normal clinical phenotype, often associated with a common recurring missense mutation c.932C>T (p.A282V) resulting in partial IVD enzyme activity reduction.

Investigation Type	Diagnostic Findings
Routine Screening Labs	High anion gap metabolic acidosis, severe ketosis, and moderate to severe hyperammonemia. Hematologic evaluation shows neutropenia, thrombocytopenia, or pancytopenia. Hypoglycemia and hypocalcemia may be present.
Newborn Screening (NBS)	Tandem Mass Spectrometry (TMS) detects elevated Isovalerylcarnitine (C5-carnitine).
Urine Organic Acids	Massive diagnostic elevation of Isovalerylglycine (hallmark) and 3-hydroxyisovaleric acid.
Confirmatory Tests	Molecular analysis of the IVD gene or specific IVD enzyme assay in cultured fibroblasts.

Dietary Arrest: Immediate cessation of exogenous protein intake for less than 24 hours.
Reversal Of Catabolism: Aggressive intravenous hydration with 10% Dextrose to halt endogenous protein breakdown.
Detoxification Therapy:
- High-dose L-Carnitine (100 mg/kg/day) to conjugate toxic isovaleric acid into non-toxic, renally excreted isovalerylcarnitine.
- Glycine supplementation (250 mg/kg/day) to enhance the formation and efficient urinary excretion of isovalerylglycine.
- Ammonia scavengers (sodium benzoate or phenylacetate) or hemodialysis for severe hyperammonemia or refractory coma.

Dietary Modification: Leucine-restricted diet titrated to age-appropriate requirements, utilizing leucine-free medical foods.
Supplementation: Chronic L-Carnitine supplementation (50-100 mg/kg/day) to prevent secondary deficiency and optional adjunctive glycine therapy.
Monitoring: Regular assessment of growth and nutritional status to prevent malnutrition secondary to over-restriction.

Early diagnosis via NBS and strict therapeutic compliance yield good outcomes with normal neurocognitive development.
High mortality rate is associated with untreated severe neonatal coma presentations.